Pfizer wins early Ibrance approval in breast cancer
This article was originally published in Scrip
The FDA on 3 February gave its approval to Pfizer to market Ibrance (palbociclib) as a treatment for metastatic breast cancer (MBC) – granting the nod more than two months ahead of schedule.
You may also be interested in...
Lilly highlighted five prognostic factors at SABCS that may be linked to high Verzenio response. As the third CDK4/6 inhibitor on the US market, the company needs to differentiate its breast cancer drug from Pfizer's Ibrance and Novartis's Kisqali.
Novartis has packaged and priced Kisqali – the second CDK4/6 inhibitor approved in the US – to compete with Pfizer's Ibrance, which made the mechanism of action the standard of care in untreated metastatic HR+/HER2- breast cancer.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.